AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
piperacillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, 6-aminopenicillanic acid derivatives | 2187 | 61477-96-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 14 | g | P |
| 14 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 714.30 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 71 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 772.85 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.27 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 4 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.50 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.96 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -1.886 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.050 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.507 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.051 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 83.110 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 63.370 | % | High | 1 |
| herg | hERG pIC50 | 4.283 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.064 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 2.958 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 83.460 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PRKDC,STK33,SYK,TEK | 24 | |||
| kinase-selectivity-class | AXL,GRK2,MAP2K6 | 3 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.089 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 1.905 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 74.990 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.820 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 68.130 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.167 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 89.700 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 67.580 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 928.966 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 29, 1981 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sepsis | 123.10 | 19.14 | 127 | 10456 | 179687 | 90438177 |
| Thrombocytopenia | 119.33 | 19.14 | 134 | 10449 | 208591 | 90409273 |
| Toxic epidermal necrolysis | 109.53 | 19.14 | 60 | 10523 | 32468 | 90585396 |
| Pyrexia | 106.27 | 19.14 | 236 | 10347 | 660249 | 89957615 |
| Acute kidney injury | 96.31 | 19.14 | 150 | 10433 | 320237 | 90297627 |
| Respiratory failure | 88.95 | 19.14 | 88 | 10495 | 118330 | 90499534 |
| Septic shock | 83.40 | 19.14 | 73 | 10510 | 84087 | 90533777 |
| Rash maculo-papular | 79.40 | 19.14 | 53 | 10530 | 40880 | 90576984 |
| Febrile neutropenia | 77.61 | 19.14 | 94 | 10489 | 158255 | 90459609 |
| Renal failure | 76.30 | 19.14 | 85 | 10498 | 130922 | 90486942 |
| Pancytopenia | 68.26 | 19.14 | 77 | 10506 | 120186 | 90497678 |
| Platelet count decreased | 68.23 | 19.14 | 82 | 10501 | 136887 | 90480977 |
| Multiple organ dysfunction syndrome | 67.14 | 19.14 | 59 | 10524 | 68277 | 90549587 |
| Dermatitis exfoliative generalised | 63.18 | 19.14 | 24 | 10559 | 5569 | 90612295 |
| Disseminated intravascular coagulation | 62.37 | 19.14 | 36 | 10547 | 21502 | 90596362 |
| Blood creatinine increased | 57.67 | 19.14 | 65 | 10518 | 101321 | 90516543 |
| Urinary tract obstruction | 54.17 | 19.14 | 17 | 10566 | 2232 | 90615632 |
| Excessive eye blinking | 53.26 | 19.14 | 15 | 10568 | 1357 | 90616507 |
| Eosinophilia | 53.06 | 19.14 | 36 | 10547 | 28497 | 90589367 |
| Leukopenia | 52.95 | 19.14 | 62 | 10521 | 100648 | 90517216 |
| Drug reaction with eosinophilia and systemic symptoms | 52.50 | 19.14 | 42 | 10541 | 42716 | 90575148 |
| Tubulointerstitial nephritis | 52.01 | 19.14 | 34 | 10549 | 25309 | 90592555 |
| Fatigue | 49.10 | 19.14 | 38 | 10545 | 1153985 | 89463879 |
| Agranulocytosis | 46.46 | 19.14 | 36 | 10547 | 34966 | 90582898 |
| Hypokalaemia | 45.87 | 19.14 | 66 | 10517 | 131050 | 90486814 |
| Oliguria | 45.42 | 19.14 | 23 | 10560 | 10601 | 90607263 |
| Joint swelling | 44.17 | 19.14 | 4 | 10579 | 503296 | 90114568 |
| Anaemia | 41.45 | 19.14 | 112 | 10471 | 352690 | 90265174 |
| Tonic clonic movements | 41.41 | 19.14 | 13 | 10570 | 1709 | 90616155 |
| Alopecia | 40.71 | 19.14 | 5 | 10578 | 495066 | 90122798 |
| Neutropenia | 40.09 | 19.14 | 84 | 10499 | 224820 | 90393044 |
| Arthralgia | 39.37 | 19.14 | 21 | 10562 | 778501 | 89839363 |
| Haemoglobin decreased | 38.05 | 19.14 | 68 | 10515 | 161888 | 90455976 |
| Pseudomembranous colitis | 38.00 | 19.14 | 15 | 10568 | 3853 | 90614011 |
| Haemolytic anaemia | 37.77 | 19.14 | 21 | 10562 | 11676 | 90606188 |
| Rash morbilliform | 37.41 | 19.14 | 15 | 10568 | 4014 | 90613850 |
| Peripheral swelling | 34.37 | 19.14 | 4 | 10579 | 413102 | 90204762 |
| Pleural effusion | 34.32 | 19.14 | 53 | 10530 | 111938 | 90505926 |
| Heparin-induced thrombocytopenia | 33.41 | 19.14 | 15 | 10568 | 5297 | 90612567 |
| Stevens-Johnson syndrome | 32.16 | 19.14 | 27 | 10556 | 29349 | 90588515 |
| Hepatic function abnormal | 32.14 | 19.14 | 33 | 10550 | 46255 | 90571609 |
| Acute generalised exanthematous pustulosis | 32.13 | 19.14 | 20 | 10563 | 13683 | 90604181 |
| Polyglandular disorder | 31.85 | 19.14 | 7 | 10576 | 227 | 90617637 |
| Headache | 31.13 | 19.14 | 33 | 10550 | 862713 | 89755151 |
| Biloma | 31.12 | 19.14 | 6 | 10577 | 100 | 90617764 |
| Hypotension | 30.21 | 19.14 | 95 | 10488 | 325302 | 90292562 |
| Clostridium difficile colitis | 30.18 | 19.14 | 25 | 10558 | 26681 | 90591183 |
| Haemophagocytic lymphohistiocytosis | 29.92 | 19.14 | 20 | 10563 | 15439 | 90602425 |
| Systemic lupus erythematosus | 28.90 | 19.14 | 4 | 10579 | 361892 | 90255972 |
| Transplant rejection | 28.35 | 19.14 | 18 | 10565 | 12740 | 90605124 |
| Weight increased | 28.29 | 19.14 | 7 | 10576 | 417920 | 90199944 |
| Cytomegalovirus infection | 28.20 | 19.14 | 24 | 10559 | 26578 | 90591286 |
| Dizziness | 28.17 | 19.14 | 17 | 10566 | 589267 | 90028597 |
| Staphylococcal sepsis | 28.01 | 19.14 | 16 | 10567 | 9367 | 90608497 |
| Hyperacusis | 27.96 | 19.14 | 11 | 10572 | 2800 | 90615064 |
| Renal impairment | 27.00 | 19.14 | 46 | 10537 | 105375 | 90512489 |
| Autoimmune haemolytic anaemia | 26.43 | 19.14 | 13 | 10570 | 5632 | 90612232 |
| Endocrine disorder | 26.26 | 19.14 | 8 | 10575 | 952 | 90616912 |
| Streptococcal infection | 25.98 | 19.14 | 14 | 10569 | 7319 | 90610545 |
| Nephropathy toxic | 25.97 | 19.14 | 17 | 10566 | 12671 | 90605193 |
| Anaemia folate deficiency | 25.96 | 19.14 | 7 | 10576 | 539 | 90617325 |
| Toxic skin eruption | 24.89 | 19.14 | 18 | 10565 | 15756 | 90602108 |
| Unresponsive to stimuli | 24.36 | 19.14 | 26 | 10557 | 38095 | 90579769 |
| Musculoskeletal stiffness | 24.34 | 19.14 | 3 | 10580 | 296529 | 90321335 |
| Abdominal discomfort | 23.90 | 19.14 | 13 | 10570 | 477315 | 90140549 |
| Product dose omission issue | 23.82 | 19.14 | 3 | 10580 | 291684 | 90326180 |
| Linear IgA disease | 22.98 | 19.14 | 9 | 10574 | 2265 | 90615599 |
| Sinusitis | 22.73 | 19.14 | 6 | 10577 | 343082 | 90274782 |
| Wound | 22.71 | 19.14 | 4 | 10579 | 302976 | 90314888 |
| Ejection fraction decreased | 22.49 | 19.14 | 21 | 10562 | 26232 | 90591632 |
| Contraindicated product administered | 22.37 | 19.14 | 5 | 10578 | 320134 | 90297730 |
| Small intestinal obstruction | 22.18 | 19.14 | 19 | 10564 | 21215 | 90596649 |
| Respiratory distress | 22.17 | 19.14 | 25 | 10558 | 38921 | 90578943 |
| Cardiac arrest | 22.03 | 19.14 | 42 | 10541 | 104893 | 90512971 |
| Cardiac failure | 21.98 | 19.14 | 43 | 10540 | 109453 | 90508411 |
| Systemic candida | 21.97 | 19.14 | 11 | 10572 | 4948 | 90612916 |
| Hypoparathyroidism | 21.77 | 19.14 | 7 | 10576 | 994 | 90616870 |
| Hydronephrosis | 21.52 | 19.14 | 15 | 10568 | 12387 | 90605477 |
| Pain in extremity | 21.51 | 19.14 | 13 | 10570 | 450516 | 90167348 |
| Aspartate aminotransferase increased | 21.37 | 19.14 | 41 | 10542 | 102896 | 90514968 |
| Leukocytosis | 21.34 | 19.14 | 22 | 10561 | 30968 | 90586896 |
| Pneumonia | 21.14 | 19.14 | 137 | 10446 | 637922 | 89979942 |
| Mental status changes | 21.00 | 19.14 | 26 | 10557 | 44653 | 90573211 |
| Aspergillus infection | 20.94 | 19.14 | 14 | 10569 | 10809 | 90607055 |
| Chronic hepatitis | 20.84 | 19.14 | 7 | 10576 | 1138 | 90616726 |
| White blood cell count decreased | 20.54 | 19.14 | 54 | 10529 | 167055 | 90450809 |
| Bronchopulmonary aspergillosis | 20.28 | 19.14 | 14 | 10569 | 11384 | 90606480 |
| Product contamination microbial | 20.08 | 19.14 | 5 | 10578 | 281 | 90617583 |
| Infusion related reaction | 19.93 | 19.14 | 12 | 10571 | 416768 | 90201096 |
| Drug intolerance | 19.89 | 19.14 | 14 | 10569 | 447577 | 90170287 |
| International normalised ratio increased | 19.81 | 19.14 | 26 | 10557 | 47290 | 90570574 |
| Epidermolysis | 19.78 | 19.14 | 6 | 10577 | 703 | 90617161 |
| Prothrombin time prolonged | 19.78 | 19.14 | 13 | 10570 | 9759 | 90608105 |
| Clostridial infection | 19.71 | 19.14 | 10 | 10573 | 4626 | 90613238 |
| Hepatic cytolysis | 19.60 | 19.14 | 21 | 10562 | 30895 | 90586969 |
| Seizure | 19.45 | 19.14 | 50 | 10533 | 152579 | 90465285 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Acute kidney injury | 112.83 | 16.19 | 313 | 13304 | 367024 | 42240694 |
| Thrombocytopenia | 108.21 | 16.19 | 207 | 13410 | 190072 | 42417646 |
| Pyrexia | 97.43 | 16.19 | 311 | 13306 | 393731 | 42213987 |
| Tubulointerstitial nephritis | 85.76 | 16.19 | 75 | 13542 | 31473 | 42576245 |
| Multiple organ dysfunction syndrome | 79.22 | 16.19 | 124 | 13493 | 96911 | 42510807 |
| Sepsis | 71.21 | 16.19 | 180 | 13437 | 199154 | 42408564 |
| Drug reaction with eosinophilia and systemic symptoms | 70.99 | 16.19 | 77 | 13540 | 41998 | 42565720 |
| Eosinophilia | 64.05 | 16.19 | 65 | 13552 | 32834 | 42574884 |
| Renal failure | 60.08 | 16.19 | 138 | 13479 | 143588 | 42464130 |
| Cholestasis | 56.90 | 16.19 | 61 | 13556 | 32818 | 42574900 |
| Agranulocytosis | 53.34 | 16.19 | 57 | 13560 | 30555 | 42577163 |
| Disseminated intravascular coagulation | 48.27 | 16.19 | 49 | 13568 | 24745 | 42582973 |
| Rash maculo-papular | 47.12 | 16.19 | 59 | 13558 | 37444 | 42570274 |
| Clostridial infection | 45.47 | 16.19 | 23 | 13594 | 3851 | 42603867 |
| Device related sepsis | 45.39 | 16.19 | 23 | 13594 | 3864 | 42603854 |
| Toxic epidermal necrolysis | 40.02 | 16.19 | 46 | 13571 | 26704 | 42581014 |
| Septic shock | 39.34 | 16.19 | 89 | 13528 | 91583 | 42516135 |
| Neutropenia | 39.03 | 16.19 | 146 | 13471 | 199285 | 42408433 |
| Renal tubular necrosis | 38.92 | 16.19 | 38 | 13579 | 18316 | 42589402 |
| Choroiditis | 38.41 | 16.19 | 15 | 13602 | 1360 | 42606358 |
| Dizziness | 38.11 | 16.19 | 16 | 13601 | 249238 | 42358480 |
| Clostridium difficile colitis | 36.01 | 16.19 | 39 | 13578 | 21213 | 42586505 |
| Rash | 35.20 | 16.19 | 178 | 13439 | 276776 | 42330942 |
| Stevens-Johnson syndrome | 34.64 | 16.19 | 39 | 13578 | 22139 | 42585579 |
| Heparin-induced thrombocytopenia | 34.09 | 16.19 | 23 | 13594 | 6574 | 42601144 |
| Death | 33.83 | 16.19 | 62 | 13555 | 471123 | 42136595 |
| Respiratory failure | 32.20 | 16.19 | 102 | 13515 | 128030 | 42479688 |
| Congenital pneumonia | 30.42 | 16.19 | 7 | 13610 | 98 | 42607620 |
| Blood alkaline phosphatase increased | 30.27 | 16.19 | 45 | 13572 | 33552 | 42574166 |
| Gamma-glutamyltransferase increased | 29.96 | 16.19 | 44 | 13573 | 32453 | 42575265 |
| Fatigue | 29.78 | 16.19 | 59 | 13558 | 435582 | 42172136 |
| Nephritis | 29.14 | 16.19 | 17 | 13600 | 3772 | 42603946 |
| Blood creatinine increased | 28.95 | 16.19 | 89 | 13528 | 109914 | 42497804 |
| Arthralgia | 28.54 | 16.19 | 15 | 13602 | 205223 | 42402495 |
| Pancytopenia | 26.23 | 16.19 | 90 | 13527 | 117653 | 42490065 |
| Rash erythematous | 26.12 | 16.19 | 41 | 13576 | 32050 | 42575668 |
| Nephropathy toxic | 25.26 | 16.19 | 29 | 13588 | 16809 | 42590909 |
| Blood bilirubin increased | 25.17 | 16.19 | 47 | 13570 | 42205 | 42565513 |
| Alanine aminotransferase increased | 24.64 | 16.19 | 73 | 13544 | 88333 | 42519385 |
| Subclavian artery occlusion | 24.07 | 16.19 | 6 | 13611 | 120 | 42607598 |
| Interstitial lung disease | 24.00 | 16.19 | 67 | 13550 | 78395 | 42529323 |
| Headache | 23.62 | 16.19 | 25 | 13592 | 239344 | 42368374 |
| Hepatic failure | 23.47 | 16.19 | 43 | 13574 | 38057 | 42569661 |
| Haemodialysis | 23.18 | 16.19 | 22 | 13595 | 10238 | 42597480 |
| Autoimmune haemolytic anaemia | 22.88 | 16.19 | 17 | 13600 | 5654 | 42602064 |
| Hepatic cytolysis | 22.82 | 16.19 | 35 | 13582 | 26809 | 42580909 |
| Off label use | 22.78 | 16.19 | 116 | 13501 | 638219 | 41969499 |
| Pneumonia staphylococcal | 22.60 | 16.19 | 14 | 13603 | 3462 | 42604256 |
| Enterobacter pneumonia | 22.57 | 16.19 | 8 | 13609 | 553 | 42607165 |
| Abdominal abscess | 22.21 | 16.19 | 16 | 13601 | 5077 | 42602641 |
| Weight increased | 21.92 | 16.19 | 4 | 13613 | 107979 | 42499739 |
| Aspartate aminotransferase increased | 21.77 | 16.19 | 64 | 13553 | 77099 | 42530619 |
| Chondritis | 21.38 | 16.19 | 6 | 13611 | 192 | 42607526 |
| Staphylococcal infection | 21.34 | 16.19 | 41 | 13576 | 37602 | 42570116 |
| Weight decreased | 21.33 | 16.19 | 21 | 13596 | 207927 | 42399791 |
| Acute respiratory distress syndrome | 21.16 | 16.19 | 36 | 13581 | 30072 | 42577646 |
| Rubber sensitivity | 21.02 | 16.19 | 7 | 13610 | 401 | 42607317 |
| Device related infection | 20.96 | 16.19 | 29 | 13588 | 20250 | 42587468 |
| Large intestine infection | 20.34 | 16.19 | 11 | 13606 | 2110 | 42605608 |
| Dialysis | 20.31 | 16.19 | 22 | 13595 | 11964 | 42595754 |
| Transplant rejection | 19.70 | 16.19 | 23 | 13594 | 13565 | 42594153 |
| Platelet count decreased | 19.65 | 16.19 | 92 | 13525 | 138489 | 42469229 |
| Pneumonia | 18.97 | 16.19 | 212 | 13405 | 421937 | 42185781 |
| Intraocular pressure increased | 18.90 | 16.19 | 16 | 13601 | 6417 | 42601301 |
| Tachycardia | 18.89 | 16.19 | 73 | 13544 | 101014 | 42506704 |
| Bacterial sepsis | 18.79 | 16.19 | 16 | 13601 | 6466 | 42601252 |
| Febrile neutropenia | 18.60 | 16.19 | 112 | 13505 | 185591 | 42422127 |
| Drug ineffective | 18.46 | 16.19 | 122 | 13495 | 630075 | 41977643 |
| Leukopenia | 18.29 | 16.19 | 59 | 13558 | 74687 | 42533031 |
| Hyperleukocytosis | 18.22 | 16.19 | 11 | 13606 | 2597 | 42605121 |
| Drug eruption | 18.11 | 16.19 | 29 | 13588 | 23046 | 42584672 |
| Toxic skin eruption | 17.87 | 16.19 | 22 | 13595 | 13708 | 42594010 |
| Muscle spasms | 17.87 | 16.19 | 3 | 13614 | 86041 | 42521677 |
| Dermatitis exfoliative | 17.83 | 16.19 | 16 | 13601 | 6931 | 42600787 |
| Febrile bone marrow aplasia | 17.80 | 16.19 | 19 | 13598 | 10162 | 42597556 |
| Bone marrow failure | 17.49 | 16.19 | 35 | 13582 | 33058 | 42574660 |
| Petechiae | 17.41 | 16.19 | 19 | 13598 | 10416 | 42597302 |
| Nasopharyngitis | 17.28 | 16.19 | 3 | 13614 | 83993 | 42523725 |
| Hypotension | 16.79 | 16.19 | 140 | 13477 | 257491 | 42350227 |
| Hepatic function abnormal | 16.72 | 16.19 | 45 | 13572 | 51522 | 42556196 |
| Tachypnoea | 16.69 | 16.19 | 27 | 13590 | 21635 | 42586083 |
| Colitis | 16.49 | 16.19 | 42 | 13575 | 46530 | 42561188 |
| Anaphylactic shock | 16.36 | 16.19 | 28 | 13589 | 23489 | 42584229 |
| Antibiotic level below therapeutic | 16.34 | 16.19 | 4 | 13613 | 74 | 42607644 |
| Organ failure | 16.30 | 16.19 | 10 | 13607 | 2430 | 42605288 |
| Hepatocellular injury | 16.22 | 16.19 | 28 | 13589 | 23650 | 42584068 |
| Renal impairment | 16.22 | 16.19 | 74 | 13543 | 110154 | 42497564 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Acute kidney injury | 204.73 | 16.11 | 399 | 20305 | 635031 | 109933564 |
| Pyrexia | 183.45 | 16.11 | 470 | 20234 | 897795 | 109670800 |
| Thrombocytopenia | 180.94 | 16.11 | 271 | 20433 | 348614 | 110219981 |
| Sepsis | 153.83 | 16.11 | 243 | 20461 | 327103 | 110241492 |
| Tubulointerstitial nephritis | 134.44 | 16.11 | 98 | 20606 | 54186 | 110514409 |
| Toxic epidermal necrolysis | 130.58 | 16.11 | 98 | 20606 | 56629 | 110511966 |
| Multiple organ dysfunction syndrome | 130.06 | 16.11 | 151 | 20553 | 151559 | 110417036 |
| Renal failure | 128.90 | 16.11 | 184 | 20520 | 226390 | 110342205 |
| Drug reaction with eosinophilia and systemic symptoms | 122.08 | 16.11 | 110 | 20594 | 81985 | 110486610 |
| Septic shock | 118.96 | 16.11 | 147 | 20557 | 157381 | 110411214 |
| Rash maculo-papular | 111.44 | 16.11 | 100 | 20604 | 74122 | 110494473 |
| Eosinophilia | 107.22 | 16.11 | 88 | 20616 | 57848 | 110510747 |
| Agranulocytosis | 88.36 | 16.11 | 81 | 20623 | 61679 | 110506916 |
| Fatigue | 79.33 | 16.11 | 67 | 20637 | 1215891 | 109352704 |
| Pancytopenia | 73.75 | 16.11 | 137 | 20567 | 209476 | 110359119 |
| Respiratory failure | 72.36 | 16.11 | 138 | 20566 | 215194 | 110353401 |
| Febrile neutropenia | 69.69 | 16.11 | 171 | 20533 | 316596 | 110251999 |
| Arthralgia | 68.82 | 16.11 | 30 | 20674 | 779602 | 109788993 |
| Disseminated intravascular coagulation | 68.71 | 16.11 | 59 | 20645 | 41227 | 110527368 |
| Joint swelling | 66.93 | 16.11 | 4 | 20700 | 442841 | 110125754 |
| Dizziness | 66.31 | 16.11 | 24 | 20680 | 698169 | 109870426 |
| Neutropenia | 65.87 | 16.11 | 186 | 20518 | 374434 | 110194161 |
| Platelet count decreased | 65.82 | 16.11 | 138 | 20566 | 230305 | 110338290 |
| Clostridium difficile colitis | 63.75 | 16.11 | 58 | 20646 | 43720 | 110524875 |
| Heparin-induced thrombocytopenia | 62.21 | 16.11 | 34 | 20670 | 11390 | 110557205 |
| Clostridial infection | 61.87 | 16.11 | 28 | 20676 | 6274 | 110562321 |
| Peripheral swelling | 60.01 | 16.11 | 4 | 20700 | 404030 | 110164565 |
| Blood creatinine increased | 59.95 | 16.11 | 116 | 20588 | 182773 | 110385822 |
| Weight increased | 57.26 | 16.11 | 6 | 20698 | 419638 | 110148957 |
| Stevens-Johnson syndrome | 56.59 | 16.11 | 56 | 20648 | 46845 | 110521750 |
| Cholestasis | 56.54 | 16.11 | 65 | 20639 | 64453 | 110504142 |
| Headache | 55.76 | 16.11 | 50 | 20654 | 882327 | 109686268 |
| Nasopharyngitis | 55.48 | 16.11 | 5 | 20699 | 394356 | 110174239 |
| Autoimmune haemolytic anaemia | 53.57 | 16.11 | 30 | 20674 | 10537 | 110558058 |
| Transplant rejection | 53.33 | 16.11 | 41 | 20663 | 24526 | 110544069 |
| Alopecia | 53.04 | 16.11 | 4 | 20700 | 364749 | 110203846 |
| Nephropathy toxic | 49.28 | 16.11 | 41 | 20663 | 27437 | 110541158 |
| Product dose omission issue | 48.32 | 16.11 | 3 | 20701 | 321779 | 110246816 |
| Leukopenia | 48.29 | 16.11 | 94 | 20610 | 148697 | 110419898 |
| Device related sepsis | 47.95 | 16.11 | 25 | 20679 | 7622 | 110560973 |
| Urinary tract obstruction | 47.67 | 16.11 | 22 | 20682 | 5155 | 110563440 |
| Renal tubular necrosis | 47.58 | 16.11 | 42 | 20662 | 30433 | 110538162 |
| Staphylococcal sepsis | 46.60 | 16.11 | 33 | 20671 | 17421 | 110551174 |
| Rheumatoid arthritis | 44.38 | 16.11 | 3 | 20701 | 299610 | 110268985 |
| Toxic skin eruption | 43.12 | 16.11 | 38 | 20666 | 27477 | 110541118 |
| Oliguria | 42.39 | 16.11 | 32 | 20672 | 18625 | 110549970 |
| Acute generalised exanthematous pustulosis | 42.37 | 16.11 | 34 | 20670 | 21630 | 110546965 |
| Hypotension | 41.57 | 16.11 | 201 | 20503 | 523648 | 110044947 |
| Pseudomembranous colitis | 40.37 | 16.11 | 21 | 20683 | 6370 | 110562225 |
| Choroiditis | 40 | 16.11 | 14 | 20690 | 1601 | 110566994 |
| Dermatitis exfoliative generalised | 39.54 | 16.11 | 25 | 20679 | 10947 | 110557648 |
| Dialysis | 38.81 | 16.11 | 31 | 20673 | 19588 | 110549007 |
| Renal impairment | 38.53 | 16.11 | 99 | 20605 | 188346 | 110380249 |
| Nephritis | 38.33 | 16.11 | 20 | 20684 | 6106 | 110562489 |
| Excessive eye blinking | 38.00 | 16.11 | 14 | 20690 | 1856 | 110566739 |
| Hepatic cytolysis | 37.74 | 16.11 | 49 | 20655 | 55004 | 110513591 |
| Pneumonia | 36.20 | 16.11 | 284 | 20420 | 876430 | 109692165 |
| Fall | 35.95 | 16.11 | 36 | 20668 | 603446 | 109965149 |
| Rash erythematous | 35.92 | 16.11 | 59 | 20645 | 81773 | 110486822 |
| Musculoskeletal stiffness | 35.70 | 16.11 | 5 | 20699 | 279817 | 110288778 |
| Staphylococcal infection | 35.64 | 16.11 | 54 | 20650 | 69890 | 110498705 |
| Escherichia infection | 35.55 | 16.11 | 32 | 20672 | 23784 | 110544811 |
| Swelling | 35.13 | 16.11 | 11 | 20693 | 351030 | 110217565 |
| Acute respiratory distress syndrome | 34.38 | 16.11 | 46 | 20658 | 53152 | 110515443 |
| Bone marrow failure | 34.33 | 16.11 | 48 | 20656 | 57800 | 110510795 |
| Rash | 33.91 | 16.11 | 266 | 20438 | 820698 | 109747897 |
| Respiratory distress | 33.44 | 16.11 | 52 | 20652 | 68822 | 110499773 |
| Abdominal discomfort | 33.37 | 16.11 | 16 | 20688 | 393842 | 110174753 |
| Pain in extremity | 32.67 | 16.11 | 26 | 20678 | 487092 | 110081503 |
| Interstitial lung disease | 32.50 | 16.11 | 77 | 20627 | 139257 | 110429338 |
| Haemoglobin decreased | 32.09 | 16.11 | 111 | 20593 | 248616 | 110319979 |
| Pulmonary oedema | 31.93 | 16.11 | 63 | 20641 | 100596 | 110467999 |
| Tachypnoea | 31.70 | 16.11 | 38 | 20666 | 39357 | 110529238 |
| Muscle spasms | 31.08 | 16.11 | 7 | 20697 | 278150 | 110290445 |
| Therapeutic product effect incomplete | 31.03 | 16.11 | 3 | 20701 | 223802 | 110344793 |
| Haemolytic anaemia | 31.01 | 16.11 | 28 | 20676 | 20892 | 110547703 |
| Pleural effusion | 30.94 | 16.11 | 88 | 20616 | 177621 | 110390974 |
| Hepatic function abnormal | 30.91 | 16.11 | 58 | 20646 | 89237 | 110479358 |
| Haemodialysis | 30.86 | 16.11 | 26 | 20678 | 17693 | 110550902 |
| Anaemia | 30.64 | 16.11 | 191 | 20513 | 546895 | 110021700 |
| Petechiae | 30.30 | 16.11 | 29 | 20675 | 23288 | 110545307 |
| Weight decreased | 30.13 | 16.11 | 26 | 20678 | 468031 | 110100564 |
| Insomnia | 30.01 | 16.11 | 15 | 20689 | 360575 | 110208020 |
| Aspergillus infection | 29.82 | 16.11 | 30 | 20674 | 25586 | 110543009 |
| Blood alkaline phosphatase increased | 29.60 | 16.11 | 50 | 20654 | 70885 | 110497710 |
| Hypokalaemia | 29.51 | 16.11 | 88 | 20616 | 182360 | 110386235 |
| Discomfort | 29.44 | 16.11 | 3 | 20701 | 214704 | 110353891 |
| Hepatic failure | 29.41 | 16.11 | 49 | 20655 | 68690 | 110499905 |
| Prothrombin time prolonged | 29.39 | 16.11 | 25 | 20679 | 17236 | 110551359 |
| Systemic candida | 29.30 | 16.11 | 20 | 20684 | 9954 | 110558641 |
| Aspartate aminotransferase increased | 28.62 | 16.11 | 80 | 20624 | 159856 | 110408739 |
| Contraindicated product administered | 28.24 | 16.11 | 6 | 20698 | 248261 | 110320334 |
| Polyglandular disorder | 28.21 | 16.11 | 7 | 20697 | 239 | 110568356 |
| Clostridium difficile infection | 27.63 | 16.11 | 41 | 20663 | 52088 | 110516507 |
| Blood bilirubin increased | 27.11 | 16.11 | 50 | 20654 | 75922 | 110492673 |
| Dry mouth | 26.89 | 16.11 | 3 | 20701 | 199945 | 110368650 |
| Drug intolerance | 26.87 | 16.11 | 22 | 20682 | 406490 | 110162105 |
| Sinusitis | 26.78 | 16.11 | 11 | 20693 | 296677 | 110271918 |
| Depression | 26.71 | 16.11 | 13 | 20691 | 317322 | 110251273 |
| Mobility decreased | 26.47 | 16.11 | 6 | 20698 | 237416 | 110331179 |
| Impaired healing | 26.33 | 16.11 | 3 | 20701 | 196714 | 110371881 |
| Enterococcal infection | 25.84 | 16.11 | 25 | 20679 | 20341 | 110548254 |
| Contusion | 25.81 | 16.11 | 6 | 20698 | 233355 | 110335240 |
| Intravascular haemolysis | 25.81 | 16.11 | 9 | 20695 | 1018 | 110567577 |
| Hyperacusis | 25.49 | 16.11 | 12 | 20692 | 2940 | 110565655 |
| Tonic clonic movements | 25.49 | 16.11 | 12 | 20692 | 2940 | 110565655 |
| Subclavian artery occlusion | 25.36 | 16.11 | 6 | 20698 | 167 | 110568428 |
| Inappropriate schedule of product administration | 25.13 | 16.11 | 4 | 20700 | 203633 | 110364962 |
| Tachycardia | 24.88 | 16.11 | 96 | 20608 | 226549 | 110342046 |
| Dermatitis exfoliative | 24.76 | 16.11 | 19 | 20685 | 11328 | 110557267 |
| Alanine aminotransferase increased | 24.56 | 16.11 | 83 | 20621 | 183690 | 110384905 |
| Bronchopulmonary aspergillosis | 24.34 | 16.11 | 29 | 20675 | 29834 | 110538761 |
| Abdominal abscess | 24.30 | 16.11 | 17 | 20687 | 8802 | 110559793 |
| Sleep disorder | 24.30 | 16.11 | 4 | 20700 | 198640 | 110369955 |
| Wound | 24.07 | 16.11 | 7 | 20697 | 234430 | 110334165 |
| Renal injury | 23.79 | 16.11 | 23 | 20681 | 18690 | 110549905 |
| Linear IgA disease | 23.72 | 16.11 | 13 | 20691 | 4376 | 110564219 |
| Mixed liver injury | 23.71 | 16.11 | 19 | 20685 | 12060 | 110556535 |
| Cytomegalovirus infection | 23.55 | 16.11 | 39 | 20665 | 54405 | 110514190 |
| Rash morbilliform | 23.49 | 16.11 | 16 | 20688 | 7935 | 110560660 |
| Antibiotic level below therapeutic | 23.16 | 16.11 | 5 | 20699 | 91 | 110568504 |
| Biloma | 23.12 | 16.11 | 6 | 20698 | 246 | 110568349 |
| Aplasia pure red cell | 23.04 | 16.11 | 17 | 20687 | 9561 | 110559034 |
| Encephalopathy | 22.48 | 16.11 | 48 | 20656 | 81007 | 110487588 |
| Treatment failure | 22.37 | 16.11 | 12 | 20692 | 277222 | 110291373 |
| Therapeutic product effect decreased | 22.14 | 16.11 | 9 | 20695 | 244307 | 110324288 |
| Pain | 22.02 | 16.11 | 98 | 20606 | 954857 | 109613738 |
| White blood cell count increased | 22.01 | 16.11 | 53 | 20651 | 96789 | 110471806 |
| Enterobacter pneumonia | 21.98 | 16.11 | 7 | 20697 | 598 | 110567997 |
| Antibiotic level above therapeutic | 21.98 | 16.11 | 8 | 20696 | 1025 | 110567570 |
| Chills | 21.97 | 16.11 | 82 | 20622 | 190498 | 110378097 |
| White blood cell count decreased | 21.87 | 16.11 | 93 | 20611 | 229297 | 110339298 |
| Bacterial sepsis | 21.75 | 16.11 | 17 | 20687 | 10409 | 110558186 |
| Febrile bone marrow aplasia | 21.33 | 16.11 | 21 | 20683 | 17444 | 110551151 |
| Endocrine disorder | 21.32 | 16.11 | 8 | 20696 | 1116 | 110567479 |
| Leukocytosis | 21.22 | 16.11 | 37 | 20667 | 53791 | 110514804 |
| Gastrooesophageal reflux disease | 21.19 | 16.11 | 4 | 20700 | 179972 | 110388623 |
| Pathogen resistance | 21.13 | 16.11 | 21 | 20683 | 17651 | 110550944 |
| Anaemia folate deficiency | 20.97 | 16.11 | 7 | 20697 | 694 | 110567901 |
| Dyspepsia | 20.94 | 16.11 | 5 | 20699 | 190960 | 110377635 |
| Injection site pain | 20.85 | 16.11 | 4 | 20700 | 177918 | 110390677 |
| Drug abuse | 20.77 | 16.11 | 4 | 20700 | 177407 | 110391188 |
| Hypoaesthesia | 20.77 | 16.11 | 17 | 20687 | 314206 | 110254389 |
| Type 2 diabetes mellitus | 20.74 | 16.11 | 4 | 20700 | 177228 | 110391367 |
| Wheezing | 20.66 | 16.11 | 11 | 20693 | 255219 | 110313376 |
| Maternal exposure during pregnancy | 20.61 | 16.11 | 11 | 20693 | 254872 | 110313723 |
| Gamma-glutamyltransferase increased | 20.20 | 16.11 | 39 | 20665 | 61270 | 110507325 |
| Neutrophilic dermatosis | 20.13 | 16.11 | 7 | 20697 | 785 | 110567810 |
| Skin exfoliation | 19.95 | 16.11 | 48 | 20656 | 87603 | 110480992 |
| Haemophagocytic lymphohistiocytosis | 19.95 | 16.11 | 27 | 20677 | 31532 | 110537063 |
| Gait disturbance | 19.73 | 16.11 | 14 | 20690 | 278194 | 110290401 |
| Osteoarthritis | 19.60 | 16.11 | 5 | 20699 | 182618 | 110385977 |
| Blood culture positive | 19.52 | 16.11 | 15 | 20689 | 8961 | 110559634 |
| Mucormycosis | 19.35 | 16.11 | 16 | 20688 | 10612 | 110557983 |
| Arthritis | 19.15 | 16.11 | 4 | 20700 | 167582 | 110401013 |
| Hepatocellular injury | 18.92 | 16.11 | 34 | 20670 | 50608 | 110517987 |
| Extravasation blood | 18.91 | 16.11 | 6 | 20698 | 507 | 110568088 |
| Mental status changes | 18.76 | 16.11 | 43 | 20661 | 76079 | 110492516 |
| Coagulopathy | 18.63 | 16.11 | 30 | 20674 | 40881 | 110527714 |
| Chondritis | 18.23 | 16.11 | 5 | 20699 | 254 | 110568341 |
| Acanthosis | 18.16 | 16.11 | 6 | 20698 | 576 | 110568019 |
| International normalised ratio increased | 18.15 | 16.11 | 46 | 20658 | 86726 | 110481869 |
| Hyperbilirubinaemia | 17.53 | 16.11 | 25 | 20679 | 30646 | 110537949 |
| Drug eruption | 17.51 | 16.11 | 34 | 20670 | 53625 | 110514970 |
| Tumour lysis syndrome | 17.45 | 16.11 | 25 | 20679 | 30776 | 110537819 |
| Pneumonia staphylococcal | 17.39 | 16.11 | 12 | 20692 | 6079 | 110562516 |
| Gastrointestinal disorder | 17.38 | 16.11 | 12 | 20692 | 241940 | 110326655 |
| Neutrophil count decreased | 17.38 | 16.11 | 56 | 20648 | 120885 | 110447710 |
| Pneumonia pseudomonal | 17.27 | 16.11 | 13 | 20691 | 7533 | 110561062 |
| Purpura | 17.17 | 16.11 | 22 | 20682 | 24366 | 110544229 |
| Colitis | 17.15 | 16.11 | 50 | 20654 | 102273 | 110466322 |
| Chronic hepatitis C | 17.07 | 16.11 | 6 | 20698 | 695 | 110567900 |
| Intraocular pressure increased | 17.00 | 16.11 | 15 | 20689 | 10861 | 110557734 |
| Hepatic infection fungal | 16.90 | 16.11 | 5 | 20699 | 334 | 110568261 |
| Intentional product use issue | 16.90 | 16.11 | 13 | 20691 | 247893 | 110320702 |
| Skin oedema | 16.87 | 16.11 | 8 | 20696 | 1991 | 110566604 |
| Neuralgic amyotrophy | 16.51 | 16.11 | 5 | 20699 | 362 | 110568233 |
| Complications of transplant surgery | 16.45 | 16.11 | 6 | 20698 | 773 | 110567822 |
| Gait inability | 16.12 | 16.11 | 3 | 20701 | 136373 | 110432222 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01CA12 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Penicillins with extended spectrum |
| ATC | J01CR05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Combinations of penicillins, incl. beta-lactamase inhibitors |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
Related Drugs by ATC class:
J01CA Penicillins with extended spectrum 18 drugs
J01CR Combinations of penicillins, incl. beta-lactamase inhibitors 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Septicemia due to Escherichia coli | indication | 9323009 | |
| Bacterial septicemia | indication | 10001005 | DOID:0040085 |
| Infection due to Pseudomonas aeruginosa | indication | 11218009 | |
| Gonorrhea | indication | 15628003 | DOID:7551 |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
| Streptococcal septicemia | indication | 29577008 | |
| Acute gonococcal urethritis | indication | 29864006 | |
| Postoperative infection | indication | 33910007 | |
| Pneumonia due to Pseudomonas | indication | 41381004 | |
| Peritonitis | indication | 48661000 | |
| Lower respiratory tract infection | indication | 50417007 | |
| Pneumonia due to Escherichia coli | indication | 51530003 | |
| Bacterial pneumonia | indication | 53084003 | DOID:874 |
| Klebsiella cystitis | indication | 60867007 | |
| Acute gonococcal endometritis | indication | 65295003 | DOID:7527 |
| Urinary tract infectious disease | indication | 68566005 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Infection due to Escherichia coli | indication | 71057007 | |
| Bacterial infection due to Serratia | indication | 71120004 | |
| Rhinoscleroma | indication | 72409005 | DOID:11336 |
| Appendicitis | indication | 74400008 | DOID:8337 |
| Abdominal abscess | indication | 75100008 | |
| Septicemia due to Bacteroides | indication | 79587009 | |
| Septicemia due to Serratia | indication | 82091000 | |
| Infection of bone | indication | 111253001 | |
| Female genital tract infection | indication | 125585007 | |
| Infectious disease of abdomen | indication | 128070006 | |
| Infection due to Enterobacteriaceae | indication | 128945009 | |
| Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
| Proteus septicemia | indication | 300986008 | |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Septicemia due to enterococcus | indication | 310669007 | |
| Infectious disorder of joint | indication | 363162000 | |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Nosocomial pneumonia | indication | 425464007 | |
| Sepsis due to Pseudomonas | indication | 448813005 | |
| Sepsis due to Gram negative bacteria | indication | 449082003 | |
| Urinary tract infection caused by Klebsiella | indication | 369001000119100 | |
| Skin and Skin Structure Bacteroides Fragilis Infection | indication | ||
| E. Coli Appendicitis | indication | ||
| Bacteroides Pneumonia | indication | ||
| Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
| Bacteroides Peritonitis | indication | ||
| Skin and Skin Structure Enterococcus Infection | indication | ||
| Prevention of Perioperative Infection | indication | ||
| Pseudomonas Aeruginosa Urinary Tract Infection | indication | ||
| Bacteroides Pelvic Inflammatory Disease | indication | ||
| Bacteroides Pelvic Cellulitis | indication | ||
| Bacteroides Endometritis | indication | ||
| E. Coli Peritonitis | indication | ||
| Pseudomonas Aeruginosa Joint Infection | indication | ||
| Bacteroides Complicated Appendicitis | indication | ||
| Enterococcus Urinary Tract Infection | indication | ||
| E. Coli Pelvic Inflammatory Disease | indication | ||
| Skin and Skin Structure Serratia Infection | indication | ||
| Bacteroides Appendicitis | indication | ||
| Neisseria Gonorrhea Pelvic Cellulitis | indication | ||
| Enterococcus Peritonitis | indication | ||
| Cesarean Section Infection Prevention | indication | ||
| Vaginal Hysterectomy Infection Prevention | indication | ||
| Enterococcus Pelvic Inflammatory Disease | indication | ||
| Bacteroides Osteomyelitis | indication | ||
| Infection Prevention for GI Surgery | indication | ||
| Enterococcus Joint Infection | indication | ||
| Clostridium Peritonitis | indication | ||
| Complicated Skin and Skin Structure Infection | indication | ||
| Inflammatory Disease of Female Pelvic Organs | indication | ||
| Pseudomonas Aeruginosa Osteomyelitis | indication | ||
| Peptostreptococcus Pelvic Inflammatory Disease | indication | ||
| Complicated Proteus UTI | indication | ||
| Staphylococcus Nosocomial Pneumonia | indication | ||
| Skin and Skin Structure Acinetobacter Infection | indication | ||
| Bacteroides Joint Infection | indication | ||
| Enterococcus Complicated UTI | indication | ||
| Skin and Skin Structure Proteus Infection | indication | ||
| Enterobacter Pneumonia | indication | ||
| E. Coli Complicated Appendicitis | indication | ||
| E. Coli Endometritis | indication | ||
| Diabetic Foot Infection | indication | ||
| Enterococcus Osteomyelitis | indication | ||
| Enterococcus Endometritis | indication | ||
| Complicated UTI with Pseudomonas Aeruginosa | indication | ||
| Skin and Skin Structure Pseudomonas Aeruginosa Infection | indication | ||
| Enterococcus Pelvic Cellulitis | indication | ||
| Ecthyma gangrenosum | off-label use | 17732003 | |
| Sepsis of the newborn | off-label use | 206376005 | |
| Diverticulitis of gastrointestinal tract | off-label use | 271366000 | |
| Pseudomonas Respiratory Tract Infection in Cystic Fibrosis | off-label use | ||
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.79 | acidic |
| pKa2 | 12.64 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Penicillin-binding protein 1A | Enzyme | WOMBAT-PK | |||||||
| Beta-lactamase | Enzyme | Ki | 6.70 | CHEMBL | |||||
| Streptokinase A | Enzyme | EC50 | 6.55 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019896 | VUID |
| N0000147981 | NUI |
| D00466 | KEGG_DRUG |
| 66258-76-2 | SECONDARY_CAS_RN |
| 59703-84-3 | SECONDARY_CAS_RN |
| 4018917 | VANDF |
| 4019896 | VANDF |
| C0031955 | UMLSCUI |
| CHEBI:8232 | CHEBI |
| WPP | PDB_CHEM_ID |
| CHEMBL702 | ChEMBL_ID |
| CHEMBL1200820 | ChEMBL_ID |
| D010878 | MESH_DESCRIPTOR_UI |
| DB00319 | DRUGBANK_ID |
| 10921 | IUPHAR_LIGAND_ID |
| X00B0D5O0E | UNII |
| 43672 | PUBCHEM_CID |
| 203134 | RXNORM |
| 1514 | MMSL |
| 5304 | MMSL |
| 60235 | MMSL |
| d00057 | MMSL |
| 002688 | NDDF |
| 004832 | NDDF |
| 11644000 | SNOMEDCT_US |
| 372836004 | SNOMEDCT_US |
| 74575000 | SNOMEDCT_US |
| X00B0D5O0E | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Zosynin Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8860 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 29 sections |
| Zosynin Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8861 | INJECTION, SOLUTION | 3 g | INTRAVENOUS | NDA | 29 sections |
| Zosynin Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8862 | INJECTION, SOLUTION | 4 g | INTRAVENOUS | NDA | 29 sections |
| Piperacillin and Tazobactam and Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0264-3446 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 28 sections |
| Piperacillin and Tazobactam and Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0264-3448 | INJECTION, SOLUTION | 3 g | INTRAVENOUS | NDA | 28 sections |
| Piperacillin and Tazobactam and Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0264-3450 | INJECTION, SOLUTION | 4 g | INTRAVENOUS | NDA | 28 sections |
| Zosyn | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0338-9632 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 29 sections |
| Zosyn | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0338-9636 | INJECTION, SOLUTION | 3 g | INTRAVENOUS | NDA | 29 sections |
| Zosyn | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0338-9638 | INJECTION, SOLUTION | 4 g | INTRAVENOUS | NDA | 29 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2999 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 12 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3383 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3385 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3390 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3110 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3113 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3114 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3117 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 12 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3180 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 36 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-9210 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-9213 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-9214 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin, Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 25021-181 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 36 g | INTRAVENOUS | ANDA | 32 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 35369-0501 | INJECTION, POWDER, FOR SOLUTION | 4 g | INTRAVENOUS | ANDA | 27 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 35369-0502 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 27 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 35369-0503 | INJECTION, POWDER, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 27 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 35369-0504 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 36 g | INTRAVENOUS | ANDA | 27 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 44567-801 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 44567-802 | INJECTION, POWDER, FOR SOLUTION | 3 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 44567-803 | INJECTION, POWDER, FOR SOLUTION | 4 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 44567-804 | INJECTION, POWDER, FOR SOLUTION | 36 g | INTRAVENOUS | ANDA | 26 sections |